title: [5-FU concentration in the serum and the tumor tissue after administration of UFT 200 mg/day to patients over 80 years of age with oral cancer].
abstract: UFT was administered orally at a dosage of 200 mg/day, 2 times a day, to patients over 80 years of age with oral cancer. The concentration of 5-FU in the serum and tumor tissue, as well as the side effects, were investigated. The results were as follows: 1. The concentration of 5-FU in the serum peaked (0.017 to 0.066 microgram/ml) 1 or 2 hours after UFT administration. The concentration 8 hours after administration was relatively high (0.016 to 0.041 microgram/ml). 2. The 5-FU concentrations in the tumor tissues in 3 out of 5 cases were greater than 0.05 microgram/g, which is considered to be the effective level. The concentration tended to be higher with increased duration of administration. 3. A minor side effect, bone marrow dysfunction, was observed. No effect on the function of the liver or digestive system was observed.
authors.affiliation: Second Dept. of Oral and Maxillofacial Surgery, Faculty of Dentistry, Niigata University.
authors.forename: A
authors.initials: A
authors.lastname: Iida
authors.forename: R
authors.initials: R
authors.lastname: Takagi
authors.forename: H
authors.initials: H
authors.lastname: Hoshina
authors.forename: K
authors.initials: K
authors.lastname: Ono
authors.forename: M
authors.initials: M
authors.lastname: Kaji
authors.forename: H
authors.initials: H
authors.lastname: Tsurumaki
authors.forename: J
authors.initials: J
authors.lastname: Fukuda
authors.forename: K
authors.initials: K
authors.lastname: Nagashima
authors.forename: Y
authors.initials: Y
authors.lastname: Miyaura
authors.forename: M
authors.initials: M
authors.lastname: Hayatsu
authors.forename: T
authors.initials: T
authors.lastname: Miyamoto
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000964:Antimetabolites, Antineoplastic / Q000097:blood* / Q000378:metabolism; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000493:pharmacokinetics; D004334:Drug Administration Schedule; D005260:Female; D005472:Fluorouracil / Q000097:blood* / Q000378:metabolism; D006801:Humans; D008297:Male; D009062:Mouth Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000378:metabolism; D005641:Tegafur / Q000008:administration & dosage* / Q000493:pharmacokinetics; D014498:Uracil / Q000008:administration & dosage* / Q000493:pharmacokinetics
chemical_list: D000964:Antimetabolites, Antineoplastic; D005641:Tegafur; D014498:Uracil; D005472:Fluorouracil